Following three studies that examined its safety and efficacy, the FDA approves the first fecal microbiota product to prevent recurring Clostridioides difficle infection in patients.
After a clinical trial showed positive results in 89% of participants, a new drug regimen was approved by the FDA for highly drug-resistant forms of pulmonary tuberculosis.
In an FDA statement, Scott Gotlieb, MD, discusses the pathogen added to the list of foodborne pathogens to routinely test for, why it was added, and the FDA’s ongoing efforts to screen domestic and imported...
The FDA has expanded the indication for a drug formerly approved for the treatment of patients with complicated intra-abdominal infections and complicated urinary tract infections.
The US Food and Drug Administration has approved a new treatment option for adult patients with complicated urinary tract infections, including pyelonephritis.